Biogen Inc. (BIIB)
$
135.91
-2.69 (-1.98%)
Key metrics
Financial statements
Free cash flow per share
12.7258
Market cap
19.9 Billion
Price to sales ratio
1.9932
Debt to equity
0.3740
Current ratio
2.5027
Income quality
1.3830
Average inventory
2.3 Billion
ROE
0.0904
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Biogen Inc. is a leader in discovering, developing, manufacturing, and delivering innovative therapies for neurological and neurodegenerative diseases. The portfolio includes treatments such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS), SPINRAZA for spinal muscular atrophy, and FUMADERM for plaque psoriasis. Additionally, the company offers BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. Furthermore, RITUXAN is provided for non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA also targets non-Hodgkin's lymphoma and CLL, while GAZYVA treats CLL and follicular lymphoma. OCREVUS is available for relapsing MS and primary progressive MS, alongside various anti-CD20 therapies. The company's pipeline includes promising candidates such as BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 for Alzheimer's disease and dementia; and BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 targeting neuromuscular disorders. Biogen also develops treatments for Parkinson's disease, neuropsychiatric conditions, immunological diseases, acute neurology, and neuropathic pain, alongside a range of biosimilars under development. The company has established collaborations and license agreements with notable entities such as Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, and Genentech, Inc. Biogen Inc. earned an interest income of $67,600,000.00 showcasing its financial investments, and reported an income before tax of $1,906,000,000.00 demonstrating its pre-tax profitability. The net income ratio is 0.17 reflecting the company's profitability margin, while the EBITDA is $2,829,500,000.00 a key indicator of its operational profitability. Additionally, the operating income ratio is 0.23 indicating solid operational performance. The stock is reasonably priced at $133.11 appealing to a broad range of investors. With a high average trading volume of 1,431,362.00 the stock indicates strong liquidity, and Biogen holds a mid-range market capitalization of $19,926,444,650.00 marking it as a steady performer in the market. It is a key player in the Drug Manufacturers - General industry, contributing significantly to the overall market landscape, and it operates within the Healthcare sector, driving innovation and growth. This combination of factors makes Biogen an attractive option for stakeholders seeking opportunities in the pharmaceutical sector, particularly in neurological treatment advancements.
Is Biogen Inc. (BIIB) a good investment?
Investing in Biogen Inc. (BIIB) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bullish outlook. Always conduct your own research before investing.
What is Biogen Inc. (BIIB)'s stock forecast?
Analysts predict Biogen Inc. stock to fluctuate between $110.04 (low) and $207.59 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Biogen Inc.'s market capitalization?
As of 2025-08-19, Biogen Inc.'s market cap is $19,926,444,650, based on 146,615,000 outstanding shares.
How does Biogen Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Biogen Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Biogen Inc. (BIIB) stock?
To buy Biogen Inc. (BIIB) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for BIIB. Place an order (Market, Limit, etc.).
What is the best time to invest in Biogen Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Biogen Inc. stock ever split?
Biogen Inc.'s last stock split was 3:1 on 2001-01-18.
How did Biogen Inc. perform in the last earnings report?
Revenue: $9,675,900,000 | EPS: $11.20 | Growth: 39.65%.
Where can I find Biogen Inc.'s investor relations reports?
Visit https://www.biogen.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Biogen Inc.?
You can explore historical data from here
What is the all-time high and low for Biogen Inc. stock?
All-time high: $351.86 (2021-08-18) | All-time low: $110.04 (2025-04-09).
What are the key trends affecting Biogen Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Biogen (BIIB) To Contact Him Directly To Discuss Their Options
globenewswire.com
– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period –
seekingalpha.com
Biogen beat Q2 2025 revenue and EPS estimates, but core MS and SPINRAZA franchises continue to erode, offset only partially by new products. Launches like ZURZUVAE and LEQEMBI show promise, yet their impact is limited by niche markets and slow adoption, tempering growth expectations. Cost discipline and improved profitability are positives, but the company's long-term growth remains challenged by declining legacy revenues and pipeline uncertainty.
seekingalpha.com
Biogen Inc. (NASDAQ:BIIB ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Alisha A. Alaimo - President & Head of North America Christopher A.
zacks.com
BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.
zacks.com
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
reuters.com
Biogen raised its annual profit forecast on Thursday, betting on strong demand for its rare disease drugs such as Skyclarys to offset declining sales of its older multiple sclerosis drugs.
zacks.com
Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.
globenewswire.com
CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for ZURZUVAE® (zuranolone) for the treatment of postpartum depression (PPD) in adults following childbirth. If approved by the European Commission (EC), ZURZUVAE will be the first treatment authorized within the European Union specifically indicated to treat depressive symptoms for women with PPD. ZURZUVAE is a once-daily, oral, 14-day treatment which was approved by the U.S. Food and Drug Administration (FDA) in 2023.
globenewswire.com
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.
See all news
